Enzymatic and chromatographic resolution procedures applied to the synthesis of the phosphoproline enantiomers by Arizpe, Alicia et al.
Graphical Abstract 
Enzymatic and chromatographic resolution 
procedures applied to the synthesis of the 
phosphoproline enantiomers 
Alicia Arizpe, María Rodríguez-Mata, Francisco J. Sayago, María J. Pueyo, Vicente Gotor, Ana I. Jiménez, Vicente Gotor-
Fernández*, Carlos Cativiela* 
N
Cbz
P
O
OMe
OMe
N
H
P
O
OMe
OMe
N
R
P
O
OMe
OMe
N
H
P
O
OH
OH
N
H
P
O
OH
OH
N
Cbz
O
R = Cbz, H
>99.5% ee >99.5% ee
94% ee 82% ee
lipase-
    catalyzed
             carbamoylation
preparative
chiral HPLC
 
Leave this area blank for abstract info. 
 Tetrahedron: Asymmetry  1
 
 
Tetrahedron: Asymmetry 
journal  homepage:  www.e lsevier .com  
 
Enzymatic and chromatographic resolution procedures applied to the 
synthesis of the phosphoproline enantiomers 
Alicia Arizpe,a María Rodríguez-Mata,b Francisco J. Sayago,a María J. Pueyo,a Vicente Gotor,b 
Ana I. Jiménez,a Vicente Gotor-Fernández,b Carlos Cativiela*,a 
a Departamento de Química Orgánica, Instituto de Síntesis Química y Catálisis Homogénea (ISQCH), CSIC–Universidad de Zaragoza, 50009 Zaragoza, 
Spain 
b Departamento de Química Orgánica e Inorgánica, Instituto Universitario de Biotecnología de Asturias, Universidad de Oviedo, 33006 Oviedo, Spain 
 
Abstract—The preparation of enantiomerically pure pyrrolidine-2-phosphonic acid (phosphoproline, ProP) has been addressed through the 
synthesis of adequate racemates and subsequent resolution by independent enzyme-catalyzed and chiral HPLC methods. First, racemic 
phosphoproline derivatives bearing the adequate protecting groups have been synthesized in excellent global yield starting from 
inexpensive materials. Preparative HPLC resolution of the N-Cbz-protected aminophosphonate on a cellulose-based column has allowed 
the isolation of optically pure enantiomers in the gram scale. Enzyme-catalyzed alkoxycarbonylation of the aminophosphonate was studied 
using different lipases, solvents and carbonates. Candida antarctica lipase type A (CAL-A) provided the highest enantioselectivity when 
combined with benzyl 3-methoxyphenyl carbonate. © 2017 Elsevier Science. All rights reserved. 
——— 
 Corresponding authors. E-mail: vicgotfer@uniovi.es, cativiela@unizar.es 
1. Introduction 
-Aminophosphonic acids, the phosphonic counterparts of 
-amino acids in which the carboxylic acid function has 
been replaced by a phosphonic acid, display a wide variety 
of biological activities that range from agrochemistry to 
medicine.1,2 Of particular relevance in the medicinal field is 
the finding that small peptides containing a C-terminal -
aminophosphonate are inhibitors of serine proteases.1–3 A 
remarkable feature is that such peptide phosphonates do not 
react with the active site of threonine, cysteine, or aspartyl 
proteases and are, therefore, specific inhibitors of serine 
proteases.4 Moreover, modification of the terminal -
aminophosphonate moiety and/or the preceding -amino 
acid residue(s) allows for considerable selectivity to target 
a particular serine protease.2,3 Thus, dipeptides containing 
phosphoproline at the C-terminus (Xaa-ProP, like those in 
Figure 1) have been shown to be selective irreversible 
inhibitors of dipeptidyl peptidase IV (DPP-IV) and closely 
related serine proteases [DPP-II, DPP8, DPP9, fibroblast 
activation protein (FAP)].2,3,5 These serine proteases cleave 
dipeptide fragments from the N-terminus of polypeptide 
chains with great specificity after a proline residue and are 
involved in the metabolism of peptide hormones that 
regulate essential physiological processes.6 As a 
consequence, inhibitors of these dipeptidyl peptidases are 
being considered as novel drug candidates for the treatment 
of prevalent diseases like diabetes, immunological 
disorders, or cancer.1–3,5,7 
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Figure 1. Structure of dipeptides shown to be specific inhibitors 
of the serine protease DPP-IV. Note that the phosphoproline 
residue is racemic. 
A feature common to the inhibition assays of DPP-IV and 
related serine proteases by phosphoproline-containing 
dipeptides is the use of diastereomeric mixtures.5 Thus, for 
these studies, racemic phosphoproline was coupled to the 
corresponding L--amino acid and the mixture of 
diastereomeric dipeptides formed was used as such for 
biological evaluation.5 Only exceptionally have the peptide 
diastereomers been separated and tested as pure 
compounds.5e,g,h This fact highlights the need for synthetic 
methodologies that provide access to the phosphoproline 
enantiomers in an efficient way and sufficient quantities. 
Ready availability of enantiopure phosphoproline 
derivatives is also essential for the development of 
applications for this structurally singular -
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aminophosphonic acid (as is proline within proteinogenic 
amino acids) in other fields such as asymmetric 
organometallic catalysis8 and organocatalysis.9  
Notwithstanding recent advances in the synthesis of -
aminophosphonic acids,1,2d,10 the development of efficient 
methodologies that provide access to optically pure 
phosphoproline remains a challenge. Actually, it is a 
subject of current interest, as evidenced by the fact that 
about half of the papers describing the isolation of the title 
compound in enantiopure or enantioenriched form11 
(through either stereoselective syntheses or resolution 
procedures) have been published in the last few years.11a–d 
Moreover, it is only recently that the absolute configuration 
of the phosphoproline enantiomers has been established in 
an unambiguous manner.11c The most successful 
diastereoselective procedures reported involve the addition 
of triethyl phosphite to a chiral oxazolopyrrolidine bearing 
a benzotriazol moiety11g or the addition of lithium diethyl 
phosphite to a chiral N-sulfinyl imine.11e An 
enantioselective approach has been described involving a 
Michael reaction between a phosphoglycine imine and 
benzyl acrylate in the presence of a chiral phase-transfer 
catalyst to furnish an (S)-phosphoproline precursor with 
85% ee.11b Chemical resolution methods were applied in 
early studies to isolate (R)- and (S)-phosphoproline by 
coupling the racemate with L-leucine and separation of the 
diastereomeric dipeptides by crystallization, followed by 
hydrolysis and purification.11i In a recent report, the 
phosphoproline enantiomers were isolated by acylation 
with dibenzoyl-L-tartaric anhydride, separation of the 
diastereomeric amides formed by column chromatography 
and hydrolysis.11a Regarding resolution by enzymatic 
methods, enantiopure (R)-phosphoproline was obtained by 
kinetic resolution of a -bromo--
(chloroacetoxy)butylphosphonate with a protease and 
further elaboration of the bromide and chloroacetoxy 
moieties and cyclization.11c In the present work, we have 
addressed the preparation of both phosphoproline 
enantiomers by resolution of a cyclic precursor using either 
enzymatic or chromatographic (chiral HPLC) procedures. 
2. Results and Discussion 
2.1. Synthesis of racemic phosphoproline derivatives 
The success of resolution procedures applied to the 
production of enantiomerically pure compounds relies, to a 
large extent, on the stage of the synthetic route selected for 
enantiomer separation. At best, the transformations 
performed on the valuable enantiomerically pure material 
obtained should be reduced to a minimum and proceed with 
high yields under conditions that do not compromise the 
chiral integrity of the stereogenic centers. With this idea in 
mind, we envisaged the resolution of a racemic 
phosphoproline precursor in which the pyrrolidine ring is 
already formed and the amino and phosphonic acid 
functions are already present and, if necessary, protected 
with groups that can be cleaved smoothly at a final step. 
This would allow the isolation of the target enantiopure -
aminophosphonic acid with minimal transformation after 
the resolution step. 
Accordingly, the first aim of the work was the preparation 
of the appropriate racemic phosphoproline precursor in an 
efficient manner. Although racemic phosphoproline (and 
small peptides containing it)  has been obtained by 
cyclization of open-chain derivatives,5h,12 most of the 
reported routes make use of starting compounds with a 
preformed pyrrolidine ring.13–15 In the majority of the latter 
cases, the phosphonate moiety was introduced by reaction 
of an alkyl/aryl phosphite with an iminium ion13,14 (Scheme 
1), which in turn was generated either by decarboxylation 
of N-substituted prolines under a variety of conditions13 
(Scheme 1, path a) or by addition of a Lewis acid to N-
protected 2-methoxypyrrolidines14 (Scheme 1, path b). The 
latter compounds can be prepared by electrochemical 
methoxylation (Scheme 1), as first reported by Shono.14,16 
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Scheme 1. Reported routes for the synthesis of racemic 
phosphoproline through an intermediate iminium ion. The 
contribution of the present work is indicated. 
We have proposed17 -lactams as alternative starting 
compounds for the convenient preparation of the 
abovementioned 2-methoxylated pyrrolidines (Scheme 1). 
The use of lactams as precursors of cyclic -
aminophosphonic acids offers several advantages. First, it 
avoids the use of electrochemical methods, which is not 
straightforward in laboratories of synthetic organic 
chemistry. Moreover, lactams can be easily transformed 
into the desired -aminophosphonates without isolation of 
any synthetic intermediate.17 Lactams of different ring size 
and bearing diverse substituents are commercial or easily 
available, thus allowing access to a wide variety of cyclic 
-aminophosphonic acids. Most importantly, 
transformation of the lactam carbonyl into a methoxy group 
ensures full regiochemical control when substituents are 
present, whereas electrochemical methoxylation may afford 
mixtures of 2- and 5-methoxylated pyrrolidines. These 
advantages have already been demonstrated in the synthesis 
of substituted phosphoproline analogues.17 
 Tetrahedron: Asymmetry  3
Accordingly, pyrrolidin-2-one (Scheme 2) was the 
substrate of choice for the preparation of the racemic 
phosphoproline derivative to be subsequently resolved by 
enzymatic or chromatographic methods. The presence of an 
N-acyl group is a prerequisite for subsequent 
transformation into an -aminophosphonate as outlined in 
Scheme 1. An acyl substituent of the carbamate type, 
namely the benzyloxycarbonyl (Z or Cbz) group, was 
selected for this purpose because final deprotection to 
liberate the amino function can be accomplished under mild 
conditions. Moreover, the aromatic unit in Cbz should 
facilitate UV detection in the HPLC experiments. 
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Scheme 2. Synthesis of racemic phosphoproline derivatives to be 
used in resolution processes. 
The Cbz group was introduced by reaction of pyrrolidin-2-
one with lithium bis(trimethylsilyl)amide and benzyl 
chloroformate (Scheme 2) to provide the N-Cbz protected 
pyrrolidinone 1. Compound 1 is also available from 
commercial sources albeit at a higher price than 
inexpensive pyrrolidin-2-one. The carbonyl group in 1 was 
reduced with diisobutylaluminium hydride to give 2. The 
unstable hemiaminal was immediately treated with catalytic 
pyridinium p-toluenesulfonate (PPTS) in methanol to form 
the methoxyaminal 3, which was not isolated but directly 
reacted with trimethyl phosphite in the presence of boron 
trifluoride-diethyl ether. The latter step proceeded via an 
intermediate N-acyliminium and provided the desired N-
Cbz-protected-aminophosphonate rac-4 in 80% overall 
yield from 1 (Scheme 2). This result highlights the utility of 
-lactams as precursors of the pyrrolidine-2-phosphonate 
moiety. In particular, the preparation of 3 from lactam 1 
proceeds in a much superior yield to that reported for the 
synthesis of similar methoxylated N-carbamoyl 
pyrrolidines by electrochemical methods.14,16 
The synthetic route in Scheme 2 allowed us to isolate the 
phosphoproline derivative rac-4 in high overall yield and 
multi-gram quantities from inexpensive pyrrolidin-2-one 
and with minimal purification of intermediate compounds 
(none purification step if starting from commercial 1). 
Compound rac-4, with protected amino and phosphonic 
acid functions, is a suitable candidate for preparative HPLC 
resolution. For the enzymatic assays, rac-4 was 
quantitatively transformed into rac-5 by catalytic 
hydrogenation under standard conditions (Scheme 2). This 
aminophosphonate should not be stored for long periods of 
time and was prepared in small quantities. 
2.2. HPLC resolution  
Based on our previous experience in the preparative-scale 
HPLC enantioseparation of protected non-natural -amino 
acids,18 we addressed the resolution of rac-4 by 
chromatographic methods using the polysaccharide-based 
columns Chiralpak® IA,19a IB,19b and IC.19c These 
stationary phases combine the excellent chiral recognition 
ability typical of polysaccharide-derived phases with high 
chemical stability.19–21 The latter feature stems from the 
covalent bonding of the chiral selector to the silica matrix, 
which makes these so-called immobilized Chiralpak® 
columns compatible with all organic solvents19–21 at 
variance with their non-immobilized counterparts, for 
which only hydrocarbon/alcohol mixtures can be used. This 
distinctiveness may not be important for analytical assays 
but is most often crucial for preparative purposes.18,21 In 
fact, the success of all our previously reported preparative 
separations on immobilized polysaccharide-based 
columns18 relied on the use of chloroform or 
dichloromethane to dissolve the sample at very high 
concentrations (typically, 500 mg of sample per mL of 
solvent or above) and, in most cases, also on the presence 
of chloroform, ethyl acetate, acetone, or tert-butyl methyl 
ether (TBME) in the eluent. All preparative HPLC 
enantioseparations previously carried out in our 
laboratories18 were performed on -amino acids of the 
carboxylic type, the present work being the first occasion 
on which the preparative HPLC resolution of an -amino 
acid of phosphonic nature is undertaken. It is worth 
mentioning that a recent HPLC analysis22 of almost 30 -
aminophosphonic acids with different structures using two 
chiral cinchona-based zwitterionic phases, Chiralpak® 
ZWIX(+) and ZWIX(–), reached baseline enantioseparation 
in both columns for all compounds tested except for 
phosphoproline and its six-membered ring homologue, 
which were not separated. 
The resolution of rac-4 was first tested at the analytical 
level using 250 × 4.6 mm Chiralpak® IA, IB and IC 
columns and eluting with n-hexane/2-propanol mixtures. 
None or very poor resolution was observed on the IA or IB 
stationary phases whereas Chiralpak® IC showed excellent 
enantiodiscrimination ability. The effect produced by the 
addition of a third component to the elution mixture was 
evaluated for the IC column. Among those tested, TBME 
proved highly detrimental to the enantioseparation, whereas 
acetone had the opposite effect. Moreover, elution with n-
hexane/acetone instead of ternary n-hexane/2-
propanol/acetone mixtures further improved the selectivity 
and resolution factors, and was also beneficial to the 
sample solubility. The analytical conditions finally selected 
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for further extension to the preparative-scale resolution of 
rac-4 were elution with a 72:28 mixture of n-
hexane/acetone on Chiralpak® IC. The chromatographic 
profile obtained under these conditions is shown in Figure 
2. 
 
Figure 2. HPLC analytical resolution of rac-4. Column: 
Chiralpak® IC (250 × 4.6 mm). Eluent: n-hexane/acetone 72:28. 
Flow rate: 1.0 mL/min. UV detection: 210 nm. 
The optimal conditions established at the analytical level 
for the resolution of rac-4 (Figure 2) were then extended to 
the preparative scale. For this purpose, a 250 × 20 mm 
Chiralpak® IC column was used and elution was performed 
with n-hexane/acetone 72:28 at 18 mL/min flow rate. The 
racemate (1.85 g) was dissolved in chloroform at very high 
concentration (1 g/mL) and 150 L aliquots of this solution 
were injected successively. More than 900 mg of each 
enantiomer were thus isolated and both of them were found 
to be optically pure (Figure 3). This means that 98% of the 
starting racemic material was recovered in enantiomerically 
pure form after a single passage through the column. 
 
Figure 3. HPLC analytical profile of the resolved enantiomers of 
4 (conditions: see Figure 2). The configuration assigned to each 
enantiomer is shown. 
Next, the protecting groups in the resolved enantiomers of 
4 were removed by treatment with a commercial solution of 
hydrogen bromide in acetic acid at room temperature and 
the resulting phosphoproline hydrobromides were 
neutralized by ion-exchange chromatography (Scheme 3). 
Comparison of the specific rotation measured for the free 
amino acids (6) with the values reported in the literature11c 
allowed us to assign an R configuration to the 
phosphoproline enantiomer derived from the first eluted 
enantiomer of 4 (Figure 3, Scheme 3). Accordingly, an S 
stereochemistry was assigned to the more strongly retained 
4 enantiomer. It is worth mentioning that the absolute 
configuration of phosphoproline was an unresolved issue 
until Hammerschmidt et al. assigned it unambiguously.11c,23 
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Scheme 3. Preparation of enantiopure phosphoproline by 
chromatographic (chiral HPLC) resolution. 
2.3. Enzymatic resolution 
Biocatalysis has received much attention in the last decades 
due to its potential in the production of enantiomerically 
pure compounds under mild reaction conditions.24,25 
However, there are very few examples26 of biocatalytic 
procedures applied to the resolution of -aminophosphonic 
acid derivatives. In fact, most of the works reporting on the 
access to these compounds by enzymatic methods are based 
on the resolution of -hydroxy- or -
acyloxyphosphonates11c,27,28 (enzyme-catalyzed acylation or 
hydrolysis reactions, respectively) followed by chemical 
transformations to replace the  OH/OCOR substituent by 
an amino group and, if necessary, to elaborate the side 
chain. This is the case of Hammerschmidt’s work 
mentioned in the Introduction11c that describes the highly 
enantioselective protease-catalyzed kinetic resolution of an 
-(chloroacetoxy)phosphonate (99% ee) and subsequent 
transformation into (R)-phosphoproline.  
To the best of our knowledge, none of the scarce examples 
of biocatalytic procedures applied to the resolution of -
aminophosphonic acid derivatives26 involves a compound 
in which the amino group is part of a cycle, as is the case in 
phosphoproline. This fact, together with our experience in 
the enzymatic resolution of - and -amino esters 
containing an azacycle,29 prompted us to explore the kinetic 
resolution of the phosphoproline precursor rac-5 by 
carbamoylation (alkoxycarbonylation) reactions. 
Hydrolases were selected for this purpose, since they have 
been shown to provide access to N-heterocyclic amines and 
amino acid derivatives with high stereocontrol.29,30 
As starting point, and based on our previous work on the 
resolution of cyclic - and -amino esters,29 
 Tetrahedron: Asymmetry  5
alkoxycarbonylation of the amino function in rac-5 was 
attempted using Candida antarctica lipase type A (CAL-A) 
and the allyl carbonates 7a-b (Scheme 4). Unfortunately, 
the reaction with diallyl carbonate (7a, 2.5 equiv.) did not 
proceed in any extension after 3 days at 30 ºC using TBME 
as solvent. For this reason, the more reactive allyl 3-
methoxyphenyl carbonate (7b)31a was tested under similar 
conditions and other lipases were included in the screening. 
Using carbonate 7b, the highest activities were observed 
for Candida antarctica lipase type B (CAL-B) and 
Pseudomonas cepacia (PSL IM), which promoted the 
reaction but in a non-selective manner, while CAL-A was 
found to catalyze the allyloxycarbonylation of 
aminophosphonate rac-5 to yield the unreacted substrate 
(S)-5 with 90% ee and the allyl carbamate (R)-8 with 20% 
ee (Scheme 4) after 92 h of reaction. These ee values were 
determined by HPLC analysis in an indirect manner since 
none of these compounds can be easily detected by UV 
absorbance. Moreover, separation of these compounds by 
silica-gel column chromatography was not possible due to 
instability observed for amine 5 under these conditions. For 
these reasons, prior to HPLC assays, the crude obtained 
from the enzymatic reaction was treated with benzyl 
chloroformate to give a mixture of optically active 
carbamates (S)-4 and (R)-8 (Scheme 4). Laborious column 
chromatography on silica gel was necessary to separate 
these carbamates as they showed similar Rf values. The 
allyloxycarbonyl group in (R)-8 was then exchanged by a 
benzyloxycarbonyl moiety through a two-step procedure 
that involved treatment with N,N-dimethylbarbituric acid 
(DMBA), triphenylphosphine and palladium acetate, and 
subsequent protection with benzyl chloroformate (Scheme 
4). The enantioenriched Cbz-protected aminophosphonates 
(S)-4 and (R)-4 obtained after these transformations and 
derived, respectively, from the unreacted amine (S)-5 and 
the allyl carbamate (R)-8 were separately subjected to 
HPLC analysis for optical purity determination. Their 
absolute stereochemistries were assigned by comparison 
with enantiomerically pure samples of (R)-4 and (S)-4 
obtained in the preparative-scale HPLC resolution process 
described above. The enantiomeric excesses determined in 
this way for the substrate (eeS) and product (eeP) were not 
consistent with a conversion value around 50%. Similar 
discrepancies were observed when the process was 
repeated and stopped at different reaction times. This 
disagreement could be due to the extensive chemical 
elaboration –including difficult purification– required prior 
to enantioselectivity determination. In particular, partial 
racemization of the product during the (R)-8-to-(R)-4 
transformation cannot be discarded. 
These difficulties prompted us to consider a change in the 
approach. Thus, to avoid the inconveniences associated 
with UV detection and purification of the allyl derivative, 
we envisaged the possibility of directly introducing a 
benzyloxycarbonyl group in rac-5. For this purpose, two 
benzyl carbonates (9a-b) were prepared following reported  
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Scheme 4. Lipase-catalyzed kinetic resolution of rac-5 using allyl carbonates 7a-b. 
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Scheme 5. CAL-A catalyzed kinetic resolution of rac-5 using benzyl carbonates 9a-b. 
procedures31b,c and their reactivity in the 
benzyloxycarbonylation of rac-5 catalyzed by CAL-A was 
studied (Scheme 5, Table 1). Carbonate 9a in TBME turned 
out to be highly reactive and produced the complete 
transformation of the starting material into the racemic 
Cbz-protected derivative rac-4. On the other hand, the use 
of benzyl 3-methoxyphenyl carbonate (9b) resulted, after 
84 h, in the formation of (R)-4 with 82% ee and the 
recovery of the starting material (S)-5 with 94% ee (Table 
1, entry 1). The enantiomeric excess of both compounds 
was determined by HPLC after transformation of the 
remaining (S)-5 into the N-tosylated phosphonate (S)-10, 
which was cleanly separated from the Cbz-derivative (R)-4 
by column chromatography on silica gel (Scheme 5). 
Enantiopure (R)-4 and (S)-4 obtained by preparative HPLC 
resolution served as reference for absolute configuration 
assignments. In an attempt to optimize enantioselectivity, 
other organic solvents were tested in the CAL-A catalyzed 
benzyloxycarbonylation of rac-5 with carbonate 9b, but 
none of them resulted in improved selectivity. Thus, no 
conversion was observed in the presence of tetrahydrofuran 
or 1,4-dioxane. Toluene and diethyl ether led to lower 
activity than TBME and produced a loss of selectivity in 
both substrate and product (Table 1, entries 2 and 3).  
Table 1. Kinetic resolution of rac-5 catalyzed by CAL-A using 
carbonate 9b in organic solvents.a 
Entry Solvent t (h) eeP (%)b eeS (%)b c (%)c Ed 
1 TBME 84 82 94 54 35 
2 Toluene 96 71 30 30 8 
3 Et2O 96 29 13 31 2 
a Enzymatic reaction conditions: 2:1 ratio CAL-A:rac-5 in weight, 
carbonate 9b (2.5 equiv.), solvent (0.07 M), 30 ºC, 250 rpm.  
b Determined by HPLC (see experimental part for details).  
c Conversion, c = eeS/(eeS+eeP).  
d E = ln[(1-c)(1-eeP)]/ln[(1-c)(1+eeP)]. 
 
Even if the enantioselectivity reached did not allow the 
isolation of enantiopure phosphoproline by these methods, 
it should be emphasized that the present work is, to the best 
of our knowledge, the first example of a biocatalytic 
resolution applied to an -aminophosphonic acid of cyclic 
structure. 
3. Conclusions 
An efficient methodology has been developed for the 
preparation of both phosphoproline enantiomers in 
optically pure form. The procedure involves the synthesis 
of a racemic phosphoproline derivative, with protected 
amino and phosphonic acid functions, and its subsequent 
chromatographic resolution by chiral HPLC. The racemic 
derivative has been synthesized from a commercially 
available N-protected pyrrolidin-2-one in a straightforward 
manner that provides the desired compound in high overall 
yield and multi-gram quantities without isolation of any 
intermediate species. The efficiency of the procedure 
highlights the great value of -lactams as precursors of the 
pyrrolidine-2-phosphonate moiety. The racemic 
phosphoproline derivative has been subjected to HPLC 
resolution on a cellulose-based chiral stationary phase. 
Specifically, a semi-preparative Chiralpak® IC column has 
allowed the enantioseparation of about 2 grams of racemate 
eluting with a mixture of n-hexane/acetone. Final removal 
of the protecting groups has provided both phosphoproline 
enantiomers in optically pure form. In addition, resolution 
of the racemic phosphoprolinate has been explored through 
enzyme-catalyzed alkoxycarbonylation reactions. From the 
hydrolases toolbox, Candida antarctica lipase type A 
(CAL-A) displayed the best activity and enantioselectivity. 
Different allyl and benzyl carbonates were tested using a 
variety of organic solvents. Under the optimal conditions, 
the unreacted aminophosphonate and the corresponding 
benzyl carbamate were obtained with good enantiomeric 
excesses (94% and 82% ee, respectively). As far as we 
know, this is the first biocatalytic resolution of a cyclic-
aminophosphonic acid.  
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4. Experimental 
4.1. General. 
Candida antarctica lipase type A (CAL-A, immobilized 
NZL-101, 5.0 U/g) was purchased from Codexis. Candida 
antarctica lipase type B (CAL-B, Novozyme 435, 7300 
PLU/g) was a gift from Novo Nordisk Co. Pseudomonas 
cepacia lipase immobilized on diatomite (PSL IM, 943 
U/g) was provided by Amano Europe. All reagents were 
used as received from commercial suppliers without further 
purification. Dowex® 50WX8 (H+ form, 50–100 mesh) 
used for ion-exchange chromatography was purchased from 
Sigma-Aldrich. Thin-layer chromatography (TLC) was 
performed on Macherey-Nagel Polygram® SIL G/UV254 
precoated silica gel polyester plates. The products were 
visualized by exposure to UV light (254 nm), ninhydrin, 
iodine vapor or ethanolic solution of phosphomolybdic 
acid. Column chromatography was performed using 60 M 
(0.04–0.063 mm) silica gel from Macherey-Nagel. Melting 
points were determined on a Gallenkamp apparatus. IR 
spectra were registered on Nicolet Avatar 360 FTIR or 
Perkin-Elmer 1720-XFT spectrophotometers; max is given 
for the main absorption bands. 1H, 13C and 31P NMR 
spectra were recorded on Bruker AV-400 or DPX-300 
instruments at room temperature using the residual solvent 
signal as the internal standard; chemical shifts () are 
expressed in ppm and coupling constants (J) in Hertz. 
High-resolution mass spectra were obtained on a Bruker 
Microtof-Q spectrometer. Optical rotations were measured 
on JASCO P-1020 or Perkin-Elmer 241 polarimeters. The 
HPLC systems used for the chromatographic and 
enzymatic resolution studies are described in the following 
sections. Carbonates 7b,31a 9a,31b and 9b31c were prepared 
following reported procedures. Racemic samples of the 
allyl derivative rac-8 and the tosyl derivative rac-10 were 
synthesized to be used as references for HPLC and/or TLC 
analysis in the enzymatic studies. 
4.2. Synthesis of N-(benzyloxycarbonyl)pyrrolidin-2-
one, 1.  
A 1 M solution of lithium bis(trimethylsilyl)amide in 
tetrahydrofuran (23.71 mL, 23.71 mmol) was slowly added 
to a solution of pyrrolidin-2-one (2.02 g, 23.71 mmol) in 
anhydrous tetrahydrofuran (60 mL) kept at –78 ºC under 
argon. After stirring at this temperature for 30 minutes, 
benzyl chloroformate (4.05 g, 3.38 mL, 23.71 mmol) was 
added dropwise. The reaction mixture was slowly warmed 
to –40 ºC and stirred at this temperature for 3 h. Then, 
saturated aqueous ammonium chloride (30 mL) was added 
and the resulting mixture was allowed to warm to room 
temperature. The two layers were separated and the 
aqueous phase was further extracted with dichloromethane 
(2  30 mL). The combined organic extracts were dried, 
filtered, and concentrated. Purification by column 
chromatography (eluent: hexanes/ethyl acetate 2:1) 
afforded 1 as an oil, which crystallized upon cooling; white 
solid (4.74 g, 21.63 mmol, 91% yield). Mp 36–37 ºC. 
Spectroscopic data were in agreement with reported 
values.32 This compound is also available from commercial 
sources. 
4.3. Synthesis of dimethyl N-
(benzyloxycarbonyl)pyrrolidine-2-phosphonate, rac-4. 
 A 1 M solution of diisobutylaluminium hydride in hexanes 
(30.70 mL, 30.70 mmol) was slowly added to a solution of 
1 (4.48 g, 20.43 mmol) in anhydrous tetrahydrofuran (100 
mL) kept at –78 ºC under argon. After stirring at this 
temperature for 2 h, the reaction was treated with saturated 
aqueous sodium acetate (30 mL) and allowed to warm to 
room temperature. A 3:1 mixture of diethyl ether and 
saturated aqueous ammonium chloride (48 mL) was then 
added and the resulting mixture was stirred until a 
suspension was formed. The solid was filtered off under 
reduced pressure and washed with diethyl ether (2  20 
mL). The organic layer was separated and the aqueous 
phase was further extracted with diethyl ether (2  30 mL). 
The combined organic extracts were washed with water (20 
mL) and brine (20 mL), dried, filtered, and evaporated to 
provide the hemiaminal 2 as an oil. It was dissolved in 
methanol (100 mL) and treated with pyridinium p-
toluenesulfonate (514 mg, 2.04 mmol). After stirring at 
room temperature for 2 h, triethylamine (884 mg, 1.22 mL, 
8.74 mmol) was added. The solvent was evaporated and the 
crude methoxyaminal 3 thus obtained was dissolved in 
anhydrous dichloromethane (80 mL) and kept under argon. 
Trimethyl phosphite (2.53 g, 2.41 mL, 20.43 mmol) was 
added and the resulting solution was cooled to –20 ºC. 
Boron trifluoride-diethyl ether (2.90 g, 2.59 mL, 20.43 
mmol) was added dropwise and the reaction mixture was 
slowly warmed to room temperature and stirred for 12 h. 
After quenching with water (20 mL), the two layers were 
separated and the aqueous phase was extracted with 
dichloromethane (2  30 mL). The combined organic 
extracts were dried, filtered, and concentrated. Purification 
by column chromatography (eluent: ethyl acetate/hexanes 
9:1) afforded rac-4 as a colorless oil (5.11 g, 16.31 mmol, 
80% yield). IR (neat)  1705, 1248, 1028 cm–1. 1H NMR 
(CDCl3, 400 MHz)  1.81–1.94 (m, 1H, H4), 1.97–2.40 (m, 
3H, H3+H4’), 3.37–3.86 (m, 8H, H5+OMe), 4.18–4.36 (m, 
1H, H2), 5.06–5.21 (m, 2H, CH2Ph), 7.21–7.44 (m, 5H, 
Ph). 13C NMR (CDCl3, 100 MHz)  (duplicate signals are 
observed for most carbons, an asterisk * indicates the minor 
rotamer) 23.5*, 24.5 (C4); 26.9, 27.7* (C3); 46.8, 47.1* 
(C5); 53.1 (d, J = 6.9 Hz, OMe); 52.9 (d, J = 6.5 Hz, OMe); 
53.2 (d, J = 162.3 Hz, C2); 67.3, 67.6* (CH2Ph); 127.9 
(Ph); 128.1 (Ph); 128.3 (Ph); 128.5 (Ph); 136.6 (Ph); 
155.1*, 155.2 (CO). 31P NMR (CDCl3, 162 MHz)  
(duplicate signal, an asterisk * indicates the minor rotamer) 
27.3*, 27.6. HRMS (ESI) C14H20NNaO5P [M+Na]+: calcd 
336.0971, found 336.0987. 
4.4. HPLC resolution of rac-4: isolation of (R)-dimethyl 
N-(benzyloxycarbonyl)pyrrolidine-2-phosphonate and 
(S)-dimethyl N-(benzyloxycarbonyl)pyrrolidine-2-
phosphonate, (R)-4 and (S)-4.  
The HPLC resolution of rac-4 was carried out on a Waters 
600 HPLC system equipped with a 2996 photodiode array 
detector (used at the analytical level) and a 2487 dual 
wavelength absorbance detector (used for the preparative-
scale resolution). Analytical assays were performed on 250 
 4.6 mm Chiralpak® IA, IB, and IC columns eluting with 
different binary or ternary mixtures (IA, IB: n-hexane/2-
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propanol; IC: n-hexane/2-propanol, n-hexane/2-
propanol/chloroform, n-hexane/2-propanol/TBME, n-
hexane/2-propanol/acetone, n-hexane/acetone) at flow rates 
ranging from 0.8 to 1.0 mL/min. The preparative resolution 
was carried out on a 250  20 mm Chiralpak® IC column 
eluting with n-hexane/acetone 72:28 at a flow rate of 18 
mL/min. The process was monitored by UV absorbance at 
215 nm. The racemate rac-4 (1.850 g) was dissolved in 
chloroform (1.85 mL) and 150 L aliquots of this solution 
were injected consecutively every 20 min. Each injection 
was collected into three separate fractions, with equivalent 
fractions of successive injections being combined. 
Evaporation of the first and third fractions provided, 
respectively, enantiomerically pure (R)-4 (909 mg) and (S)-
4 (905 mg). The second fraction (17 mg) was found to 
contain a 33:67 mixture of (R)-4/(S)-4 and was discarded. 
(R)-4: colorless oil, []D22 = –60.0 (c 0.53, CHCl3).  
(S)-4: colorless oil, []D22 = +61.3 (c 0.52, CHCl3).  
Spectroscopic data were identical to those obtained for rac-
4. 
4.5. Synthesis of (R)-pyrrolidine-2-phosphonic acid, (R)-
phosphoproline, (R)-6.  
A 33% solution of hydrogen bromide in acetic acid (8 mL) 
was added to (R)-4 (400 mg, 1.28 mmol) and the reaction 
mixture was stirred at room temperature for 2 h. The 
solvent was evaporated and the residue was submitted to 
ion-exchange chromatography on Dowex® 50WX8 (H+ 
form, 50–100 mesh) eluting with water. Lyophilization of 
the aqueous solution afforded (R)-6 as a white solid (193 
mg, 1.28 mmol, 100% yield); mp 272–274 ºC (lit.11c 265–
270 ºC). []D21 = –49.8 (c 1.1, 1 M NaOH) {lit.11c []D20 = –
49.1 (c 1.1, 1 M NaOH)}. Spectroscopic data were in 
agreement with reported values.11c 
4.6. Synthesis of (S)-pyrrolidine-2-phosphonic acid, (S)-
phosphoproline, (S)-6.  
An identical procedure to that described above was applied 
to transform (S)-4 (400 mg, 1.28 mmol) into (S)-6 (193 mg, 
1.28 mmol, 100% yield); mp 272–274 ºC. []D21 = +51.1 (c 
1.1, 1 M NaOH). Spectroscopic data were identical to those 
obtained for (R)-6. 
4.7. Synthesis of dimethyl pyrrolidine-2-phosphonate, 
rac-5.  
A mixture of rac-4 (200 mg, 0.64 mmol) and 10% Pd/C (20 
mg) in ethanol (10 mL) was stirred overnight at room 
temperature under an atmospheric pressure of hydrogen 
gas. Filtration of the catalyst and evaporation of the solvent 
provided rac-5 as a colorless oil (115 mg, 0.64 mmol, 
100% yield). IR (neat)  3315, 1247, 1031 cm–1. 1H NMR 
(CDCl3, 400 MHz)  1.61–2.24 (m, 5H, NH+H3+H4), 2.81–
2.89 (m, 1H, H5), 2.92–3.00 (m, 1H, H5’), 3.25–3.32 (m, 
1H, H2), 3.72 (d, J = 10.4 Hz, 3H, OMe), 3.73 (d, J = 10.4 
Hz, 3H, OMe). 13C NMR (CDCl3, 100 MHz)  26.0 (d, J = 
8.1 Hz, C4), 26.7 (C3), 47.6 (d, J = 11.6 Hz, C5), 53.0 (d, J 
= 4.0 Hz, OMe), 53.0 (d, J = 4.1 Hz, OMe), 53.6 (d, J = 
164.7 Hz, C2). 31P NMR (CDCl3, 162 MHz)  31.1. HRMS 
(ESI) C6H14NNaO3P [M+Na]+: calcd 202.0604, found 
202.0613. 
4.8. General procedure for the enzymatic kinetic 
resolution of rac-5.  
To a suspension of rac-5 and the lipase (1:2 in weight) in 
dry solvent (0.07 M) kept under a nitrogen atmosphere was 
added carbonate 7a-b or 9a-b (2.5 equiv.). The system was 
shaken at 30 ºC and 250 rpm until conversion was around 
50% (TLC, eluent: ethyl acetate). The enzyme was filtered 
and washed with tetrahydrofuran (5 × 2 mL). The solvent 
was evaporated and the crude obtained was elaborated in 
one of the following ways: 
A) Carbonates 7a-b (see Scheme 4): The crude was treated 
with benzyl chloroformate in the presence of N,N-
diisopropylethylamine (similarly to that described in 
section 4.9) to give a mixture of enantioenriched (S)-4 and 
(R)-8. The two carbamates were separated by column 
chromatography on silica gel (eluent: ethyl acetate). 
Enantioenriched (R)-8 was transformed into (R)-4 by 
treatment with N,N-dimethylbarbituric acid, 
triphenylphosphine and palladium acetate (as described in 
ref. 33; no purification was performed) and subsequent 
reaction with benzyl chloroformate in the presence of N,N-
diisopropylethylamine (similarly to that described in 
section 4.9). The enantioenriched N-Cbz derivatives (S)-4 
and (R)-4 obtained were subjected to HPLC analysis for ee 
determination. 
B) Carbonates 9a-b (see Scheme 5): The crude was treated 
with tosyl chloride in the presence of triethylamine (as 
described for the synthesis of rac-10) to give a mixture of 
enantioenriched N-tosyl and N-Cbz derivatives (S)-10 and 
(R)-4. The two compounds were separated by column 
chromatography on silica gel (eluent: ethyl acetate) and 
subjected to HPLC analysis for ee determination. 
HPLC elution times and conditions: (R)-4 9.5 min, (S)-4 
11.8 min; (S)-10 18.0 min, (R)-10 30.9 min; Hewlett 
Packard 1100 chromatograph, 250  4.6 mm Chiralcel® OJ-
H column, 30 ºC, n-hexane/ethanol 85:15, 0.8 mL/min flow 
rate, UV monitoring at 210 nm. Samples of rac-4, rac-10, 
and enantiopure (R)-4 and (S)-4 (from the preparative 
HPLC resolution, see above) were used as references for 
retention times and absolute configuration assignment.  
(S)-10: []D20 = +76.7 (c 1.0, CHCl3) for 94% ee; 
spectroscopic data were identical to those obtained for rac-
10. 
4.9. Synthesis of dimethyl N-
(allyloxycarbonyl)pyrrolidine-2-phosphonate, rac-8. 
N,N-Diisopropylethylamine (74 mg, 99 L, 0.57 mmol) 
was added to a solution of rac-5 (82 mg, 0.46 mmol) in 
anhydrous tetrahydrofuran (3 mL) kept at room 
temperature under an argon atmosphere. The mixture was 
cooled to 0 ºC and allyl chloroformate (69 mg, 60 L, 0.57 
mmol) was added. The reaction mixture was allowed to 
warm to room temperature and stirred overnight. The 
solvent was evaporated and the crude was purified by 
column chromatography (eluent: ethyl acetate) to afford 
rac-8 as a colorless oil (57 mg, 0.22 mmol, 47% yield). IR 
(neat)  1704, 1648, 1248, 1029 cm–1. 1H NMR (CDCl3, 
400 MHz)  1.80–1.93 (m, 1H, H4), 1.95–2.30 (m, 3H, 
H3+H4’), 3.35–3.59 (m, 2H, H5), 3.64–3.80 (m, 6H, OMe), 
4.17–4.30 (m, 1H, H2), 4.51–4.62 (m, 2H, CH2CH=), 5.13–
5.20 (m, 1H, CH=CH2), 5.22–5.34 (m, 1H, CH=CH2), 
 Tetrahedron: Asymmetry  9
5.82–5.96 (m, 1H, CH=CH2). 13C NMR (CDCl3, 100 MHz) 
 (duplicate signals are observed for most carbons; an 
asterisk * indicates the minor rotamer) 23.4*, 24.5 (C4); 
26.8, 27.6* (C3); 46.7, 46.9* (C5); 52.9 (d, J = 6.6 Hz, 
OMe); 53.1 (d, J = 7.2 Hz, OMe); 53.1 (d, J = 162.3 Hz, 
C2); 66.1, 66.4* (CH2CH=); 117.5, 117.9* (CH=CH2); 
132.8 (CH=CH2); 155.0 (CO). 31P NMR (CDCl3, 162 
MHz)  (duplicate signal, an asterisk * indicates the minor 
rotamer) 27.3*, 27.7. HRMS (ESI) C10H18NNaO5P 
[M+Na]+: calcd 286.0815, found 286.0833. 
4.10. Synthesis of dimethyl N-tosylpyrrolidine-2-
phosphonate, rac-10. 
Triethylamine (12 mg, 17 L, 0.12 mmol) was added to a 
solution of rac-5 (17 mg, 0.09 mmol) in anhydrous 
tetrahydrofuran (1 mL) kept at room temperature under an 
argon atmosphere. The mixture was cooled to 0 ºC and 
tosyl chloride (23 mg, 0.12 mmol) was added. The reaction 
mixture was allowed to warm to room temperature and 
stirred for 6 h. After evaporation of the solvent, the residue 
was purified by column chromatography (eluent: ethyl 
acetate) to afford rac-10 as a white solid (16 mg, 0.05 
mmol, 51% yield). Mp 119–120 ºC. IR (KBr)  1348, 
1309, 1263, 1189, 1158, 1037 cm–1. 1H NMR (CDCl3, 300 
MHz)  1.35–1.49 (m, 1H, H4), 1.52–1.72 (m, 1H, H4’), 
1.89–2.11 (m, 2H, H3), 2.39 (s, 3H, Me), 3.34–3.41 (m, 2H, 
H5), 3.77 (d, J = 10.5 Hz, 3H, OMe), 3.84 (d, J = 10.5 Hz, 
3H, OMe), 4.07–4.16 (m, 1H, H2), 7.28 (d, J = 8.2 Hz, 2H, 
Ph), 7.69 (d, J = 8.2 Hz, 2H, Ph). 13C NMR (CDCl3, 75 
MHz)  21.6 (Me), 24.5 (C4), 27.0 (C3), 49.3 (C5), 53.0 (d, 
J = 6.9 Hz, OMe), 54.2 (d, J = 7.2 Hz, OMe), 55.3 (d, J = 
171.2 Hz, C2), 127.6 (Ph), 129.9 (Ph), 134.8 (Ph), 144.0 
(Ph). 31P NMR (CDCl3, 121 MHz)  26.1. HRMS (ESI) 
C13H20NNaO5PS [M+Na]+: calcd 356.0692, found: 
356.0721. 
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